Although high-dose chemotherapy may cure a small subset of patients with myelodysplastic
syndrome (MDS), allogeneic hematopoietic cell transplantation (HCT) is the only currently …

Supportive care remains the mainstay of therapy for patients with myelodysplastic syndrome
(MDS). Although allogeneic bone marrow transplantation is the only known curative therapy …

Hematopoietic cell transplantation (HCT) offers potentially curative therapy for patients with
myelodysplastic syndromes (MDS). However, who should and can be transplanted, with …

Allogeneic hematopoietic cell transplantation (HCT) offers the only potential cure for patients
with myelodysplastic syndromes (MDS). However, with current approaches to HCT, many …

Transplantation is the only known cure for myelodysplastic syndrome (MDS). While some
comparative analyses have demonstrated early transplantation to be the preferred strategy …

Myelodysplastic syndrome (MDS) is a stem cell disorder, and hematopoietic stem cell
transplantation is currently the only therapeutic modality that is potentially curative. Among …

The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic
cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated …

The term myelodysplastic syndrome (MDS) describes a spectrum of disorders that are
characterized by dysplastic marrow cell morphology, the development of peripheral blood …

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for
patients with myelodysplastic syndrome (MDS). Because MDS predominantly affects an …

A recent American Society of Blood and Marrow Transplantation (ASBMT) position paper
concluded that allogeneic hematopoietic cell transplantation (HCT) is recommended for …